Karyopharm Therapeutics Inc. provided earnings guidance for the year 2024. Total revenue to be in the range of $140 million to $160 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.105 USD | +2.31% | +4.72% | +28.32% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.32% | 126M | |
-1.21% | 103B | |
+8.30% | 101B | |
+4.40% | 23.07B | |
-12.08% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.24% | 16.94B | |
+6.51% | 14.07B | |
+38.76% | 12.35B |
- Stock Market
- Equities
- KPTI Stock
- News Karyopharm Therapeutics Inc.
- Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Year 2024